{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T22:25:15Z","timestamp":1778883915908,"version":"3.51.4"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.msard.2020.102456","type":"journal-article","created":{"date-parts":[[2020,8,19]],"date-time":"2020-08-19T22:57:44Z","timestamp":1597877864000},"page":"102456","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["Resolution of myelin oligodendrocyte glycoprotein (MOG)-IgG optic neuritis without treatment"],"prefix":"10.1016","volume":"46","author":[{"given":"Amir R.","family":"Vosoughi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4911-9152","authenticated-orcid":false,"given":"Jonathan A.","family":"Micieli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.msard.2020.102456_bib0001","doi-asserted-by":"crossref","DOI":"10.1136\/practneurol-2017-001787","article-title":"Myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease: practical considerations","volume":"19","author":"Jury\u0144czyk","year":"2019","journal-title":"Pract Neurol"},{"issue":"2","key":"10.1016\/j.msard.2020.102456_bib0002","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1111\/ene.14089","article-title":"Clinical, imaging and follow-up study of optic neuritis associated with myelin oligodendrocyte glycoprotein antibody: a multicentre study of 62 adult patients","volume":"27","author":"Shor","year":"2020","journal-title":"Eur J Neurol"},{"issue":"6","key":"10.1016\/j.msard.2020.102456_bib0003","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000163","article-title":"Antibodies to MOG in adults with inflammatory demyelinating disease of the CNS","volume":"2","author":"Kim","year":"2015","journal-title":"Neurol Neuroimmunol NeuroInflammation"},{"issue":"1","key":"10.1016\/j.msard.2020.102456_bib0004","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1186\/s12974-016-0718-0","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 2: epidemiology, clinical presentation, radiological and laboratory features, treatment responses, and long-term outcome","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflammation"},{"issue":"4","key":"10.1016\/j.msard.2020.102456_bib0005","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1177\/1352458515593406","article-title":"Radiological differentiation of optic neuritis with myelin oligodendrocyte glycoprotein antibodies, aquaporin-4 antibodies, and multiple sclerosis","volume":"22","author":"Ramanathan","year":"2016","journal-title":"Mult Scler"},{"key":"10.1016\/j.msard.2020.102456_bib0006","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.ajo.2018.07.020","article-title":"Myelin Oligodendrocyte Glycoprotein Antibody\u2013Positive Optic Neuritis: clinical Characteristics, Radiologic Clues, and Outcome","volume":"195","author":"Chen","year":"2018","journal-title":"Am J Ophthalmol"},{"key":"10.1016\/j.msard.2020.102456_bib0007","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.jneuroim.2016.09.007","article-title":"Different etiologies and prognoses of optic neuritis in demyelinating diseases","volume":"299","author":"Akaishi","year":"2016","journal-title":"J Neuroimmunol"},{"issue":"4","key":"10.1016\/j.msard.2020.102456_bib0008","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1001\/jamaophthalmol.2017.6757","article-title":"Prevalence of Myelin Oligodendrocyte Glycoprotein and Aquaporin-4-IgG in Patients in the Optic Neuritis Treatment Trial","volume":"136","author":"Chen","year":"2018","journal-title":"JAMA Ophthalmol"},{"issue":"2","key":"10.1016\/j.msard.2020.102456_bib0009","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1177\/1120672118784797","article-title":"Clinical presentation of optic neuritis with autoantibodies anti-myelin oligodendrocyte glycoprotein","volume":"29","author":"Ducloyer","year":"2019","journal-title":"Eur J Ophthalmol"},{"key":"10.1016\/j.msard.2020.102456_bib0010","doi-asserted-by":"crossref","first-page":"340","DOI":"10.3389\/fneur.2018.00340","article-title":"Progressive Demyelination in the Presence of Serum Myelin Oligodendrocyte Glycoprotein-IgG: a Case Report","volume":"9","author":"Gil-Perotin","year":"2018","journal-title":"Front Neurol"},{"key":"10.1016\/j.msard.2020.102456_bib0011","doi-asserted-by":"crossref","DOI":"10.1016\/j.jneuroim.2019.577078","article-title":"The clinical presentation and treatment of MOG antibody disease at a single academic center: a case series","volume":"337","author":"Brayo","year":"2019","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.msard.2020.102456_bib0012","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.jns.2018.11.029","article-title":"The prevalence and prognostic value of myelin oligodendrocyte glycoprotein antibody in adult optic neuritis","volume":"396","author":"Liu","year":"2019","journal-title":"J Neurol Sci"},{"issue":"10","key":"10.1016\/j.msard.2020.102456_bib0013","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1136\/bjophthalmol-2017-311177","article-title":"Clinical features of demyelinating optic neuritis with seropositive myelin oligodendrocyte glycoprotein antibody in Chinese patients","volume":"102","author":"Zhao","year":"2018","journal-title":"Br J Ophthalmol"},{"issue":"8","key":"10.1016\/j.msard.2020.102456_bib0014","doi-asserted-by":"crossref","DOI":"10.1111\/ene.13932","article-title":"Uveitis and optic perineuritis in the context of myelin oligodendrocyte glycoprotein antibody seropositivity","volume":"26","author":"Ramanathan","year":"2019","journal-title":"Eur J Neurol"},{"issue":"1","key":"10.1016\/j.msard.2020.102456_bib0015","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/01658107.2019.1607883","article-title":"Myelin Oligodendrocyte Glycoprotein Antibody (MOG-IgG)-Positive Optic Perineuritis","volume":"44","author":"Lopez-Chiriboga","year":"2019","journal-title":"Neuroophthalmology"},{"issue":"7","key":"10.1016\/j.msard.2020.102456_bib0016","doi-asserted-by":"crossref","first-page":"866","DOI":"10.1177\/1352458514555785","article-title":"Antibodies to MOG and AQP4 in adults with neuromyelitis optica and suspected limited forms of the disease","volume":"21","author":"H\u00f6ftberger","year":"2015","journal-title":"Mult Scler"},{"issue":"3","key":"10.1016\/j.msard.2020.102456_bib0017","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.clim.2010.11.013","article-title":"Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases","volume":"138","author":"Di Pauli","year":"2011","journal-title":"Clin Immunol"},{"issue":"11","key":"10.1016\/j.msard.2020.102456_bib0018","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.1001\/jamaneurol.2018.1814","article-title":"Association of MOG-IgG Serostatus With Relapse After Acute Disseminated Encephalomyelitis and Proposed Diagnostic Criteria for MOG-IgG-Associated Disorders","volume":"75","author":"L\u00f3pez-Chiriboga","year":"2018","journal-title":"JAMA Neurol"},{"issue":"1","key":"10.1016\/j.msard.2020.102456_bib0019","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1186\/s12974-016-0717-1","article-title":"MOG-IgG in NMO and related disorders: a multicenter study of 50 patients. Part 1: frequency, syndrome specificity, influence of disease activity, long-term course, association with AQP4-IgG, and origin","volume":"13","author":"Jarius","year":"2016","journal-title":"J Neuroinflammation"},{"issue":"10","key":"10.1016\/j.msard.2020.102456_bib0020","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1136\/jnnp-2017-315998","article-title":"Longitudinal analysis of myelin oligodendrocyte glycoprotein antibodies in CNS inflammatory diseases","volume":"88","author":"Hyun","year":"2017","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"14","key":"10.1016\/j.msard.2020.102456_bib0021","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1177\/1352458518811597","article-title":"Persistent MOG-IgG positivity is a predictor of recurrence in MOG-IgG-associated optic neuritis, encephalitis and myelitis","volume":"25","author":"Oliveira","year":"2019","journal-title":"Mult Scler"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820305319?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034820305319?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:54:42Z","timestamp":1761900882000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034820305319"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":21,"alternative-id":["S2211034820305319"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2020.102456","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Resolution of myelin oligodendrocyte glycoprotein (MOG)-IgG optic neuritis without treatment","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2020.102456","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"102456"}}